Dorie Makropoulos
Overview
Explore the profile of Dorie Makropoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiong F, Janko M, Walker M, Makropoulos D, Weinstock D, Kam M, et al.
Int Immunopharmacol
. 2014 Aug;
22(2):465-79.
PMID: 25107440
The possible onset of Cytokine Release Syndrome (CRS) is an important consideration in the development of monoclonal antibody (mAb) therapeutics. In this study, several machine learning approaches are used to...
2.
Rafferty P, Egenolf D, Brosnan K, Makropoulos D, Jordan J, Meshaw K, et al.
J Immunotoxicol
. 2012 Feb;
9(1):43-55.
PMID: 22299716
Many immunosuppressive drugs are associated with an increased risk of neoplasia, principally non-melanoma skin cancers and B-cell lymphomas. However, only 6 of the 13 immunosuppressive drugs tested in 2 year...
3.
Egenolf D, Rafferty P, Brosnan K, Walker M, Jordan J, Makropoulos D, et al.
J Pharmacol Toxicol Methods
. 2010 Dec;
63(3):236-49.
PMID: 21156211
Introduction: Immunosuppressive drugs are associated with an increased risk of infections and in some cases neoplasia, particularly non-melanoma skin cancers. This paper describes the development of a model to test...
4.
Walker M, Makropoulos D, Achuthanandam R, Bugelski P
Curr Opin Drug Discov Devel
. 2010 Jan;
13(1):124-35.
PMID: 20047153
Infusion reactions and cytokine release syndrome (CRS) are an emerging issue in drug development and are of particular importance with the development of new therapeutic proteins. Increasing concerns regarding patient...
5.
Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, et al.
Blood
. 2009 Mar;
113(20):4955-62.
PMID: 19264917
Anemia as associated with numerous clinical conditions can be debilitating, but frequently can be treated via administration of epoetin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-beta. Despite the complexity of EPO-EPO receptor interactions,...
6.
Bugelski P, Nesspor T, Volk A, OBrien J, Makropoulos D, Shamberger K, et al.
Pharm Res
. 2007 Jul;
25(2):369-78.
PMID: 17609863
Purpose: Originally approved for three times/week dosing, recombinant human erythropoietin (rhEPO) is now often used at weekly intervals. We have studied rhEPO in mice to better understand why the extended...